Introduction
============

To date, colorectal cancer (CRC) has become one of the most common human malignant diseases and a leading cause of cancer-related deaths in China and worldwide [@B1], [@B2]. The survival outcome of CRC patients is largely impaired by the development of distant metastatic disease. The liver, in addition to being the most common site of metastases, is also the first area of metastatic spread in 25% of patients at diagnosis [@B3]. In addition, approximately 25-35% of patients ultimately develop liver metastases during the course of their disease [@B4]. Despite recent advances in chemotherapy strategies for the treatment of patients with colorectal liver metastases (CRLM), liver resection offers the only chance of long-term survival for these patients [@B5]-[@B7]. Unfortunately, more than 60% of patients developed recurrent disease after initial liver resection during follow-up [@B8], [@B9]. Among those with postoperative recurrence, 27.8-45% of patients even developed early recurrent disease within 6 to 8 months after liver resection [@B10], [@B11]. Therefore, the management of CRLM is challenging, and understanding the tumor biological behavior of CRLM is important to help establish and optimize therapeutic strategies. Although multiple clinical risk factors are commonly adopted in the identification of different risk subgroups, a proportion of patients remain incorrectly assessed because of the inconsistent predictive power and lack of reproducibility due to selection bias [@B12], [@B13]. Identification of novel biomarkers to screen out various prognostic risk subgroups to guide individual treatment for CRLM is urgently needed.

Wnt/β-catenin alterations are prominent in human malignancies and participate in tumorigenesis and tumor progression by increasing tumorigenicity, sustaining proliferation, and enhancing metastatic potential [@B14], [@B15]. The Wnt gene family consists of structurally related genes that encode a group of 19 secreted and cysteine-rich signaling proteins [@B16]. Wnt family member 6 (WNT6), as a member of the Wnt signaling family, has been reported to be involved in promoting the proliferation and differentiation of embryonic palatal mesenchymal cells, macrophages, and stromal cells [@B17]-[@B19]. In addition to its vital functions in embryonic development, WNT6 also contributes to tumorigenesis [@B20]. Furthermore, previous studies have reported that WNT6 is overexpressed in gastric cancer and esophageal cancer, which indicates unfavorable survival after tumor resection [@B21], [@B22]. However, the prognostic value of WNT6 expression in patients with CRLM undergoing liver resection remains unclear. Overexpression of WNT6 is involved in colon cancer cell progression and promotes proliferation, cell cycle and migration [@B23]. Accordingly, we hypothesized that WNT6 is a direct measure of tumor biology and may be a powerful predictor of survival outcome in CRC patients.

To further validate our hypothesis, the present study aimed to explore the prognostic value of WNT6 and its relationship with clinicopathologic characteristics in patients with colorectal liver-only metastasis (CLOM) undergoing liver resection.

Materials and methods
=====================

Patient selection
-----------------

Paraffin-embedded tumor tissue samples of primary tumors were obtained from 106 consecutive CRLM patients who underwent tumor resection at the Sun Yat-sen University Cancer Center (Guangzhou, China) from October 1996 to December 2011. All included patients met the following inclusion criteria: (1) histologically confirmed colorectal adenocarcinoma; (2) American Society of Anesthesiologists (ASA) class I-II status; (3) no preoperative extrahepatic metastases; (4) radical resection for both colorectal primary tumor and liver metastasis; and (5) a postoperative follow-up period of at least 3 months. The patient demographics, tumor characteristics, adjuvant chemotherapy and follow-up data were retrospectively collected from the electronic medical record system. The tumor stage was classified according to the 2010 American Joint Committee on Cancer staging system. The treatment strategy and operability of liver metastases for each patient were determined according to the final agreement of the multidisciplinary team (MDT) as previously described [@B24]. The present study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. Informed consent for the use of tissue samples was obtained from the patients before tumor resection. The study was approved by the Institutional Research Ethics Committee of Sun Yat-sen University Cancer Center (Approval number: GZR2017-004).

Immunohistochemistry
--------------------

The paraffin-embedded tissues were sectioned continuously into 4-μm-thick sections. The tissue sections were dewaxed in xylene, rehydrated and rinsed in graded ethanol solutions. The antigens were retrieved by heating the tissue sections at 100 °C for 5 min in EDTA (1 mmol/L, pH 8.0) solution when necessary. The sections were then immersed in a 0.3% hydrogen peroxide solution for 10 min to block endogenous peroxidase activity, rinsed in phosphate buffered saline (PBS) for 5 min, and incubated with the WNT6 primary antibody (1:200 dilution, ab50030; Abcam, Cambridge, MA, USA) at 4 °C overnight. Subsequently, the slides were washed with 1× PBS and treated with a goat antibody against a mouse/rabbit secondary antibody (Envision; Dako, Glostrup, Denmark) at 37.5 °C for 30 min. Finally, the visualized staining was developed with 3,3\'-diaminobenzidine tetrahydrochloride (DAB, Dako, Glostrup, Denmark), and all of the slides were counterstained with hematoxylin.

Immunohistochemical scoring
---------------------------

The immunohistochemistry (IHC) score of WNT6 expression was determined by the semiquantitative method according to the percentage and intensity of positively stained cells as we previously described [@B25], [@B26]. The positive staining was scored as follows: "0" (less than 5% positively stained cells), "1" (5-24% positively stained cells), "2" (25-49% positively stained cells), "3" (50-74% positively stained cells), and "4" (75-100% positively stained cells). The intensity was scored as follows: "0" (negative staining); "1" (weak staining); "2" (moderate staining); and "3" (strong staining). The final score was generated by multiplying the percentage score by the staining intensity score. Two independent observers blindly evaluated the IHC score of WNT6 expression in all specimens. The cut-off value of WNT6 expression was determined by the median IHC score. High WNT6 expression grade was defined when the IHC score was greater than the cut-off value.

Recurrence risk assessment
--------------------------

Recurrence risk in all CRLM patients after liver resection was evaluated by Fong clinical risk score (CRS) system [@B27]. The scoring system consisted of 5 clinical factors: (1) node-positive primary tumor, (2) largest metastasis \> 5 cm, (3) multiple liver metastases, (4) preoperative carcinoembryonic antigen (CEA) level \> 200 ng/mL, and (5) disease-free interval from primary tumor resection to the diagnosis of liver metastasis \< 12 months. Based on the number of risk factors, each patient was allocated a CRS. Accordingly, patients with a CRS of 0-2 were identified as the low-risk subgroup, while patients with a CRS of 3-5 were identified as the high-risk subgroup.

Follow-up
---------

Patients were monitored through subsequent visits every 3 months for the first 2 years and then semiannually for 5 years after liver resection. Clinical examination, assessment of CEA and carbohydrate antigen 19-9 (CA19-9) levels, and chest radiography were conducted every 3 months. Chest/abdominal/pelvic CT and colonoscopy were performed annually. Overall survival (OS) was defined as the interval from the date of liver resection to the date of death from any cause or to the last follow-up. Recurrence-free survival (RFS) was defined as the interval from tumor resection to the date of disease recurrence, death or the last follow-up. Random censoring was applied to patients without recurrence or death at the last follow-up date. The final follow-up visit occurred in May 2018.

Statistical analysis
--------------------

All analyses were performed using IBM SPSS statistics software, version 21.0 (IBM Corp., Armonk, NY, USA). Categorical variables are presented as percentages, and they were compared using the chi-square test or Fisher\'s exact test. Continuous variables are presented as the median (range). Mann-Whiney U test was used for two-group comparison, and Kruskal-Wallis H test was used for multiple-group comparison. Survival outcomes were summarized by the Kaplan-Meier method and log-rank survival analysis. Parameters for which P \< 0.05 for OS in the univariate Cox models were further assessed in multivariate Cox models. Hazard ratios (HRs) and 95% confidence intervals (CIs) were subsequently calculated. All of the statistical tests were two-sided; P \< 0.05 was considered significant.

Results
=======

Patient characteristics
-----------------------

A total of 106 eligible patients with CRLM were included in the present study. The clinical information is summarized in detail in Table [1](#T1){ref-type="table"}. The mean age at diagnosis was 58 years (range, 25-77 years), with 69 (65.1%) males and 37 (34.9%) females. The median number of liver metastases in patients was 1 (range 1-11). With regard to CRS, 63 (49.4%) patients were classified into the low-risk group (CRS 0-2), while 63 (50.6%) patients were classified into the high-risk group (CRS 3-5). Regarding perioperative treatment, 31 (29.2%) patients received preoperative chemotherapy, 94 (88.7%) patients received adjuvant chemotherapy, and 11 (10.4%) patients received intraoperative radiofrequency ablation.

Association of WNT6 expression with clinicopathologic characteristics
---------------------------------------------------------------------

As shown in Figure [1](#F1){ref-type="fig"}, positive staining of WNT6 was mainly located in the cytoplasm of the cells, which was observed in 93.4% (99/106) of colorectal cancer tissues. As presented in Figure [2](#F2){ref-type="fig"}, the cut-off value in WNT6 expression was the median IHC score of 2. Accordingly, a high expression level of WNT6 in tumor cells was noted in samples from 52 (49.1%) patients. Subsequently, we assessed the association of WNT6 expression in tumor tissues with the following clinicopathologic parameters: age, sex, tumor location, tumor size, primary tumor differentiation, T stage, N stage, number and size of liver metastatic tumors, preoperative CEA and CA19-9 levels, perioperative chemotherapy, and survival outcome. The associations between clinicopathological features and WNT6 expression in tumor cells from 106 CRLM patients are summarized in Table [2](#T2){ref-type="table"}. High WNT6 expression was associated with a higher mortality rate after liver resection than low WNT6 expression (65.5% vs. 46.3%, P = 0.048). No significant association was found between WNT6 expression and other clinicopathological characteristics. The median IHC scores of WNT6 expression in CRS 1, CRS 2, CRS 3 and CRS 4 were 1.67 (range 0.67-8.00), 2.00 (range 0.00-12.00), 2.33 (range 0.00-11.00) and 2.00 (range 0.67-7.33), respectively, which were not significantly different (P = 0.995, Figure [3](#F3){ref-type="fig"}A). However, the median IHC score of WNT6 expression in patients receiving preoperative chemotherapy was significantly lower than the score of those without preoperative chemotherapy \[1.33 (range 0.00-7.33) vs. 2.33 (range 0.00-12.00), P = 0.033, Figure [3](#F3){ref-type="fig"}B\].

Association between WNT6 expression and survival outcome
--------------------------------------------------------

After liver resections, all patients were followed up for a median of 35.5 months (range: 2.0-143.3 months). Overall, 72 (67.9%) patients experienced tumor recurrence, including 45.8% (33/72) patients with intrahepatic recurrence, 6.9% (5/72) patients with lung metastases, 5.6% (4/72) patients with abdominal pelvic metastases, 11.8% (10/106) patients with multiple organ metastases, and 27.8% (20/72) patients with other metastases. As a result, 59 (55.7%) patients died of tumor progression. Regarding the total patients, the 3- and 5-year RFS rates were 33.9% and 30.6%, respectively, and the 3- and 5-year OS rates were 54.9% and 47.0%, respectively. The 5-year RFS did not significantly differ between the high and low WNT6 groups (24.9% vs. 36.2%, P = 0.205, Figure [4](#F4){ref-type="fig"}A). However, the 5-year OS rates were significantly lower in the high WNT6 group than in the low WNT6 group (31.0% vs. 62.2%, P = 0.012, Figure [4](#F4){ref-type="fig"}B). The patients were further stratified as low risk for recurrence (CRS 1-2) or high risk (CRS 3-4). Among the low-risk patients, the 5-year OS rate was significantly lower in the high WNT6 group than in the low WNT6 group (36.8% vs. 79.9%, P = 0.013, Figure [5](#F5){ref-type="fig"}A). Among the high-risk patients, the 5-year OS rate was comparable between the high and low WNT6 groups (22.7% vs. 34.7%, P = 0.433, Figure [5](#F5){ref-type="fig"}B).

As shown in Table [3](#T3){ref-type="table"}, the univariate analysis revealed that high WNT6 expression (HR: 1.920; 95% CI: 1.143-3.225; P = 0.014), N stage 1-2 (HR: 1.922; 95% CI: 1.034-3.572; P = 0.039), more than 3 liver metastases (HR: 2.481; 95% CI: 1.320-4.663; P = 0.005), high preoperative CA19-9 (HR: 2.194; 95% CI: 1.302-3.696; P = 0.003) and intraoperative radiofrequency ablation (HR: 2.291; 95% CI: 1.081-4.855; P = 0.031) were significant negative predictors of 5-year OS. Multivariate analysis showed that WNT6 expression (HR: 2.089; 95% CI: 1.231-3.545; P = 0.006), N stage (HR: 2.131; 95% CI: 1.132-4.015; P = 0.019), number of liver metastatic tumors (HR: 2.318; 95% CI: 1.220-4.405; P = 0.010) and preoperative CA19-9 level (HR: 1.931; 95% CI: 1.135-3.286; P = 0.015) were identified as independent predictors of 5-year OS.

Discussion
==========

To further understand tumorigenesis and explore significant biomarkers to predict long-term survival in CRLM, the present study evaluated WNT6 expression in tumor tissue of CRLM patients for the first time. Our data show that WNT6 is commonly expressed in colon cancer tumor tissues. Furthermore, overexpression of WNT6 in tumor tissue was correlated with poor OS in CRLM patients, especially in those with low-risk CRLM. Our results also indicate that WNT6 expression was an independent prognostic factor for 5-year OS. These results implied that WNT6 might be used as a potential prognostic biomarker for CRLM.

Several molecular mechanisms could contribute to the reduced long-term survival observed with high WNT6 expression in CRLM patients. WNT6 promotes tumorigenesis and progression of colon cancer [@B23], and overexpression of WNT6 may increase the expression of caspase-3 and MMP2. It is well known that MMP2 is involved in the proteolytic degradation of the extracellular matrix, which subsequently promotes the epithelial to mesenchymal transition (EMT), a key process involved in cancer metastasis[@B28], [@B29]. Moreover, WNT6 was also confirmed to be an important component of EMT initiation [@B30]. These findings suggest that WNT6 plays an important role in maintaining metastatic aggressiveness in CRC cells. Chemotherapy resistance is another factor that compromises the prognosis of CRLM patients. Our data showed that patients receiving preoperative chemotherapy presented significantly lower WNT6 expression than those without preoperative chemotherapy (P = 0.033). We hypothesized that chemotherapy decreases the expression level of WNT6 in CRLM and that the effect of chemotherapy might be associated with WNT6 expression. If high expression of WNT6 after chemotherapy was detected, the effect of chemotherapy might be not approving. A previous study indicated that WNT6 was able to facilitate the development of resistance to chemotherapeutic drugs [@B21], [@B31]. The increased WNT6 expression rendered tumor cells resistant to apoptosis, thus favoring tumor cell survival and further progression [@B21]. In addition, enhancing the expression of WNT6 increases the cisplatin resistance of bladder cancer cells [@B31]. Accordingly, we considered WNT6 to be a potential target to overcome chemoresistance in cancer patients.

Although WNT6 expression was not significantly associated with CRS, we found that WNT6 expression was associated with OS in low-risk patients but not in high-risk patients. We considered this to be mainly attributed to the disparate characteristics between different-risk CRLM patients. CRLM patients with CRS 0-2 have a highly favorable outcome, while patients with a CRS of 3-5 have a much more guarded prognosis [@B27], [@B32]. As clinical risk factors accumulate, their effect on prognosis increases.

In addition, Ayez N et al. study has demonstrated that traditional CRS systems including Fong system are not a reliable prognostic tool when used in patients before treatment with preoperative chemotherapy except for the Nordlinger CRS system [@B33]. In fact, there were 29.2% patients were performed preoperative chemotherapy in the current study, which might affect the prognostic analysis value of Fong CRS system. Therefore, the prognostic predictive effect of WNT6 expression is more difficult to discern. This finding suggested that the long-term survival of low-risk patients might be more susceptible to WNT6 expression.

Based on the result of our study, the feasibility of WNT6 expression could be used to categorize CRLM patients as a stratification parameter for different prognosis. In addition, the detection of WNT6 expression could also help clinicians tailor adjuvant treatment in a comprehensive transversal approach. Accordingly, if patients were identified as high WNT6 expression, they might be benefit from a more aggressive postoperative chemotherapy, even targeted therapy and a more normative follow-up measurement. Otherwise, patients with low WNT6 expression tumors, they might have less benefit from postoperative chemotherapy as they presented a favorable prognosis. Accordingly, the enhanced postoperative chemotherapy should be avoided. Therefore, they can be spared the associated toxicity, cost, and inconvenience of over-treatment. Taken together, detection of WNT6 expression might be useful to personalizing treatment which allows patients to maximize benefits while minimizing harms, thus providing optimal survival benefit and quality of life.

Some limitations of this study should be acknowledged. First, this retrospective study was conducted with an uncontrolled methodology and included a limited number of patients from a single center. Therefore, the findings need to be validated in multicenter studies or larger cohort studies. Second, liver metastatic tumors were not included in this study to detect WNT6 expression. This limitation may have led to an underestimation of the prognostic impact of WNT6 on the long-term survival of CRLM patients. Moreover, molecular features of tumors, such as microsatellite instability (MSI), CpG island methylator phenotype (CIMP) level, and BRAF and KRAS mutational status, were not evaluated in this study; an analysis of the association of WNT6 with these molecular markers would help us further understand the impact of WNT6 on tumorigenesis in CRLM. Future studies should examine these biomarkers. Despite these limitations, our findings suggest that WNT6 expression should be considered a routine postoperative measurement for CRLM patients undergoing liver resection.

In conclusion, this study demonstrated that WNT6 expression is a valuable predictor of OS in patients with CRLM undergoing hepatic resection. Herein, the detection of WNT6 expression may help surgeons evaluate the benefit of curative hepatectomy and formulate individualized strategies for postoperative treatment.
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![The IHC score of WNT6 expression in 106 patients with colorectal liver metastasis (CRLM). The red dotted line indicates the cut-off value in WNT6 expression as the median IHC score of 2.](jcav10p2619g002){#F2}

![Expression level of WNT6 in different clinical risk scores (CRS) patients and patients with or without preoperative chemotherapy. (A) The expression level of WNT6 was comparable in different CRS patients (P = 0.995). (B) The expression level of WNT6 was significantly lower in patients with preoperative chemotherapy than in those without preoperative chemotherapy (P = 0.003).](jcav10p2619g003){#F3}

![Kaplan-Meier long-term survival curves grouped by high and low WNT6 expression in CRLM patients. (A) Recurrence-free survival (RFS) in all patients. (B) Overall survival (OS) in all patients.](jcav10p2619g004){#F4}

![Kaplan-Meier curves for the comparison of long-term survival rates based on different WNT6 expression in high- and low-risk patients. (A) OS of patients with low-risk CRLM. (B) OS of patients with high-risk CRLM.](jcav10p2619g005){#F5}

###### 

Clinical data of 106 cases of colorectal liver metastasis patients

  Parameters                               Total patients (n, %)
  ---------------------------------------- -----------------------
  **Patient characteristics**              
  Median age (year)                        58 (25-77)
  Age, year                                
  ≤60                                      62 (58.5)
  \>60                                     44 (41.5)
  Sex                                      
  Male                                     69 (65.1)
  Female                                   37 (34.9)
  Primary tumor location                   
  Right-side colon                         28 (26.4)
  Left-side colon                          38 (35.8)
  Rectum                                   40 (37.7)
  Primary tumor differentiation            
  Well                                     2 (1.9)
  Moderate                                 89 (84.0)
  Poor                                     15 (14.1)
  T stage                                  
  2                                        8 (7.5)
  3                                        36 (34.0)
  4                                        62 (58.5)
  N stage                                  
  0                                        33 (31.1)
  1                                        39 (36.8)
  2                                        34 (32.1)
  Timing of liver metastasis               
  Synchronous                              99 (93.4)
  Metachronous                             7 (6.6)
  Number of liver metastatic tumors        
  1                                        56 (52.8)
  2                                        23 (21.7)
  3                                        8 (7.5)
  4                                        4 (3.8)
  5                                        2 (1.9)
  \>5                                      13 (12.3)
  Metastases diameter (cm)                 
  Median (range)                           2.5 (0.5-12)
  ≤3                                       67 (63.2)
  \>3                                      39 (36.8)
  Preoperative CEA (ng/ml)                 
  ≤10                                      49 (46.2)
  \>10                                     57 (53.8)
  Preoperative CA19-9 (U/ml)               
  ≤35                                      74 (69.8)
  \>35                                     32 (30.2)
  Clinical risk score                      
  1                                        17 (16.0)
  2                                        46 (43.4)
  3                                        31 (29.2)
  4                                        12 (11.3)
  Intraoperative radiofrequency ablation   
  Yes                                      11 (10.4)
  No                                       95 (89.6)
  Preoperative chemotherapy                
  Yes                                      31 (29.2)
  No                                       75 (70.8)
  Adjuvant chemotherapy                    
  Yes                                      12 (11.3)
  No                                       94 (88.7)

Abbreviations: CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9

###### 

Association of the expression of WNT6 and clinicopathologic parameters in all patients

  Parameters                               Low WNT6 expression (n=54, %)   High WNT6 expression (n=52, %)   P value
  ---------------------------------------- ------------------------------- -------------------------------- ---------
  Age, year                                                                                                 
  ≤60                                      35 (64.8)                       27 (51.9)                        0.178
  \>60                                     19 (35.2)                       25 (48.1)                        
  Sex                                                                                                       
  Male                                     37 (68.5)                       32 (61.5)                        0.451
  Female                                   17 (31.5)                       20 (38.5)                        
  Primary tumor location                                                                                    
  Right-side colon                         15 (27.8)                       13 (25.0)                        0.856
  Left-side colon                          20 (37.0)                       18 (34.6)                        
  Rectum                                   19 (35.2)                       21 (40.4)                        
  Primary tumor differentiation                                                                             
  Well to moderate                         46 (85.2)                       45 (86.5)                        0.842
  Poor                                     8 (14.8)                        7 (13.5)                         
  T stage                                                                                                   
  1-3                                      21 (38.9)                       22 (42.3)                        0.720
  4                                        33 (61.1)                       30 (57.7)                        
  N stage                                                                                                   
  0                                        16 (29.6)                       17 (32.7)                        0.734
  1-2                                      38 (70.4)                       35 (67.3)                        
  Number of liver metastatic tumors                                                                         
  1-3                                      45 (83.3)                       42 (80.8)                        0.731
  \>3                                      9 (16.7)                        10 (19.2)                        
  Metastases diameter (cm)                                                                                  
  ≤3                                       37 (68.5)                       30 (57.7)                        0.248
  \>3                                      17 (31.5)                       22 (42.3)                        
  Preoperative CEA (ng/ml)                                                                                  
  ≤10                                      26 (48.1)                       23 (44.2)                        0.686
  \>10                                     28 (51.9)                       29 (55.8)                        
  Preoperative CA19-9 (U/ml)                                                                                
  ≤35                                      40 (74.1)                       34 (65.4)                        0.330
  \>35                                     14 (25.9)                       18 (34.6)                        
  Intraoperative radiofrequency ablation                                                                    0.307
  Yes                                      4 (7.4)                         7 (13.5)                         
  No                                       50 (92.6)                       45 (86.5)                        
  Preoperative chemotherapy                                                                                 
  Yes                                      34 (63.0)                       41 (78.8)                        0.072
  No                                       20 (37.0)                       11 (21.2)                        
  Adjuvant chemotherapy                                                                                     
  Yes                                      48 (88.9)                       46 (88.5)                        0.945
  No                                       6 (11.1)                        6 (11.5)                         
  Postoperative recurrence                                                                                  
  Yes                                      34 (63.0)                       38 (73.1)                        0.265
  No                                       20 (37.0)                       14 (26.9)                        
  Survival status                                                                                           
  Alive                                    29 (53.7)                       18 (34.6)                        0.048
  Dead                                     25 (46.3)                       34 (65.5)                        

Abbreviations: TNM stage: tumor-node-metastasis classification, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9

###### 

Univariate and multivariate Cox regression analysis of overall survival in patients with colorectal liver metastasis after liver resection

                                                              Univariate                       Multivariate          
  ----------------------------------------------------------- --------------------- ------- -- --------------------- -------
  Age (≤60 year vs. \>60 year)                                1.004 (0.597-1.689)   0.987                            
  Sex (Male vs. Female)                                       1.140 (0.660-1.969)   0.638                            
  Primary tumor location (Rectum vs. Colon)                   1.145 (0.682-1.921)   0.609                            
  Primary tumor differentiation (Poor vs. Well to moderate)   1.097 (0.520-2.316)   0.807                            
  T stage (4 vs. 1-3)                                         1.256 (0.741-2.131)   0.397                            
  N stage (1-2 vs. 0)                                         1.922 (1.034-3.572)   0.039      2.131 (1.132-4.015)   0.019
  Number of liver metastatic tumors (\>3 vs. 1-3)             2.481 (1.320-4.663)   0.005      2.318 (1.220-4.405)   0.010
  Metastases diameter (\>3 cm vs. ≤3 cm)                      1.462 (0.872-2.453)   0.150                            
  Preoperative CEA (\>10 ng/ml vs. ≤10 ng/ml)                 1.688 (0.999-2.851)   0.050                            
  Preoperative CA19-9 (\>35 U/ml vs. ≤35 U/ml)                2.194 (1.302-3.696)   0.003      1.931 (1.135-3.286)   0.015
  Intraoperative radiofrequency ablation (Yes vs. No)         2.291 (1.081-4.855)   0.031      1.773 (0.728-4.320)   0.208
  Preoperative chemotherapy (Yes vs. No)                      1.065 (0.604-1.878)   0.826                            
  Adjuvant chemotherapy (Yes vs. No)                          0.857 (0.389-1.888)   0.702                            
  WNT6 expression (High vs. Low)                              1.920 (1.143-3.225)   0.014      2.089 (1.231-3.545)   0.006

Abbreviations: CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9
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